费城染色体阳性急性淋巴细胞白血病（Ph+ ALL）患者使用 ponatinib 或 imatinib 治疗的患者报告结局：PhALLCON 试验结果 ——ponatinib 为 Ph+ ALL 一线治疗带来新希望 《Leukemia》：Patient-reported outcomes in Philadelphia chromosome-positive acute lymphoblastic ...

Breelyn Wilky, MD, explains when patients with gastrointestinal stromal tumor should be referred for clinical trials.

目的：探索使用伊马替尼（Imatinib）替代剂型治疗患者的可能性。方法：对两名患者使用不同的肠内和直肠伊马替尼剂型进行治疗。在治疗期间测量血浆浓度，以确保有足够的药物暴露量。结果：第一名患者通过十二指肠管接受伊马替尼悬浮液治疗。剂量为 400mg Bid 时，患者的伊马替尼血浆浓度为 ...

Breelyn Wilky, MD, discusses what key molecular insights in GIST management community oncologists should prioritize today.

Imatinib is a highly effective treatment for chronic myeloid leukaemia. However, patients often develop resistance to this ABL kinase inhibitor. This Review discusses second generation inhibitors ...

This review discusses the development and uses of imatinib mesylate, a protein tyrosine kinase inhibitor useful in the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumors ...

Among patients with newly diagnosed chronic-phase CML who are receiving imatinib, the long-term outcome is more favorable for those in whom a complete cytogenetic response is achieved at 12 months ...

To determine the clinical efficacy of imatinib in patients with advanced aggressive fibromatosis (AF) and to identify the molecular basis of response/nonresponse to this agent.

Learn about side effects, uses, cost, and more for imatinib oral tablets. This is a generic drug that treats certain types of cancer in adults and some children.

4 Consideration of the evidence The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of imatinib as an adjuvant treatment, having considered evidence on the ...

Bosutinib is a potent dual SRC/ABL kinase inhibitor approved for adults with Philadelphia chromosome–positive chronic myeloid leukemia (CML) resistant and /or intolerant to prior therapy. We assessed ...